Darren J Kelly

List of Publications by Citations

204 papers	9,390 citations	57 h-index	86 g-index
211 ext. papers	10,264 ext. citations	5.7 avg, IF	5.54 L-index

#	Paper	IF	Citations
204	Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. *Diabetes*, **1999**, 48, 2229-39	0.9	388
203	Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. *Heart Rhythm*, **2013**, 10, 90-100	6.7	233
202	Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. *European Heart Journal*, **2010**, 31, 1771-9	9.5	211
201	The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. *Hypertension*, **2009**, 54, 261-9	8.5	205
200	Retinal neovascularization is prevented by blockade of the renin-angiotensin system. *Hypertension*, **2000**, 36, 1099-104	8.5	201
199	Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. *Diabetologia*, **2002**, 45, 1572-6	10.3	188
198	Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. *Circulation Research*, **2003**, 93, 246-53	15.7	184
197	Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. *Diabetologia*, **2000**, 43, 1360-7	10.3	161
196	Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. *Diabetes*, **2003**, 52, 512-8	0.9	151
195	Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. *Diabetologia*, **2007**, 50, 2398-404	10.3	150
194	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. *Journal of Hepatology*, **2001**, 35, 376-85	13.4	139
193	Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. *Heart Rhythm*, **2010**, 7, 1282-90	6.7	132
192	A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). *Kidney International*, **1998**, 54, 343-52	9.9	129
191	Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. *Circulation Research*, **2012**, 111, 1470-83	15.7	127
190	Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. *Diabetologia*, **2001**, 44, 878-82	10.3	126
189	Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. *American Journal of Pathology*, **1999**, 155, 429-40	5.8	121
188	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14448-53	11.5	116

187	Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. *American Journal of Pathology*, **2011**, 178, 2205-14	5.8	114
186	Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. *Diabetologia*, **2002**, 45, 268-75	10.3	113
185	Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. *PLoS ONE*, **2012**, 7, e41281	3.7	107
184	Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor- *Cardiovascular Therapeutics*, **2012**, 30, e30-40	3.3	102
183	eNOS deficiency predisposes podocytes to injury in diabetes. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 1810-23	12.7	102
182	Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. *American Journal of Pathology*, **2004**, 164, 1263-73	5.8	99
181	PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. *Kidney International*, **2001**, 59, 1324-32	9.9	98
180	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. *Kidney International*, **2000**, 58, 2437-51	9.9	98
179	The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. *American Journal of Pathology*, **2003**, 162, 151-60	5.8	97
178	Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. *Circulation: Heart Failure*, **2009**, 2, 129-37	7.6	92
177	Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 294, H1804-14	5.2	92
176	Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. *Nephrology Dialysis Transplantation*, **2002**, 17, 1327-32	4.3	91
175	Expression, localization, and function of the thioredoxin system in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 730-41	12.7	89
174	PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 554-66	12.7	89
173	High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. *Cardiovascular Diabetology*, **2014**, 13, 89	8.7	88
172	Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2098-2107	12.7	88
171	COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 974-9		87
170	Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. *American Journal of Kidney Diseases*, **2004**, 44, 826-831	7.4	87

169	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. *Cardiovascular Research*, **2005**, 65, 694-701	9.9	84
168	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 298, H1415-25	5.2	81
167	ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. *Diabetes*, **2002**, 51, 3283-9	0.9	80
166	Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. *Hypertension* , **2000**, 36, 561-8	8.5	77
165	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. *Kidney International*, **2000**, 57, 1882-94	9.9	74
164	Short-term hypertension is associated with the development of atrial fibrillation substrate: a study in an ovine hypertensive model. *Heart Rhythm*, **2010**, 7, 396-404	6.7	73
163	Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. *Endocrinology*, **2008**, 149, 3286-93	4.8	70
162	Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1654-60	12.7	69
161	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. *Kidney International*, **2002**, 61, 31-9	9.9	68
160	High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. *American Journal of Pathology*, **2007**, 171, 744-54	5.8	67
159	Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. *Kidney International*, **1999**, 71, S31-6	9.9	67
158	Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. *Kidney International*, **1998**, 54, 1052-62	9.9	66
157	Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F1388-96	4.3	66
156	Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. *Scientific Reports*, **2016**, 6, 29196	4.9	65
155	Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. *PLoS ONE*, **2013**, 8, e72416	3.7	65
154	Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. *Circulation Research*, **2000**, 86, 158-65	15.7	65
153	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. *Cardiovascular Research*, **2007**, 76, 280-91	9.9	64
152	Microglia activation in the hypothalamic PVN following myocardial infarction. *Brain Research*, **2010**, 1326, 96-104	3.7	63

151	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 213-21	5.8	63
150	High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. *Kidney International*, **2005**, 68, 985-97	9.9	62
149	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. *Diabetic Medicine*, **2003**, 20, 607-21	3.5	60
148	Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2006**, 290, F205-13	4.3	57
147	Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. *Kidney International*, **2004**, 66, 1805-14	9.9	57
146	Mast cell infiltration and chemokine expression in progressive renal disease. *Kidney International*, **2003**, 64, 906-13	9.9	56
145	Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. *American Journal of Physiology - Heart and Circulatory Physiology*, **2012**, 302, H1884-93	5.2	52
144	Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 2619-29	12.7	52
143	Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. *FASEB Journal*, **2015**, 29, 540-53	0.9	51
142	Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. *PLoS ONE*, **2010**, 5, e9543	3.7	51
141	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H2860-9	5.2	50
140	Plasmin is not protective in experimental renal interstitial fibrosis. *Kidney International*, **2004**, 66, 68-76	9.9	50
139	Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. *Nephrology*, **2011**, 16, 573-81	2.2	49
138	SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 1600-5		48
137	Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. *Diabetes Care*, **2006**, 29, 2670-5	14.6	47
136	Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. *Nephrology Dialysis Transplantation*, **2002**, 17, 985-91	4.3	47
135	Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. *Hypertension*, **2004**, 44, 195-202	8.5	46
134	Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. *Nephron Physiology*, **2003**, 95, p83-91		46

133	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 193-208	6.9	44
132	Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?. *Kidney International*, **2007**, 72, 481-8	9.9	43
131	Over-expression of platelet-derived growth factor in human diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2003**, 18, 1392-6	4.3	43
130	Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. *Diabetes Care*, **2007**, 30, 995-6	14.6	42
129	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. *Cardiovascular Diabetology*, **2011**, 10, 80	8.7	41
128	Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. *American Journal of Pathology*, **2009**, 175, 1858-67	5.8	41
127	Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. *Nephron Physiology*, **2007**, 106, p54-62		41
126	Expression during rat fetal development of GLUT12--a member of the class III hexose transporter family. *Anatomy and Embryology*, **2002**, 205, 441-52		41
125	Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. *Kidney International*, **1999**, 56, 211-21	9.9	41
124	Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 7003-6	2.9	40
123	Cardiac Repair With a Novel Population of Mesenchymal Stem Cells Resident in the Human Heart. *Stem Cells*, **2015**, 33, 3100-13	5.8	39
122	Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 2117-29	5.6	38
121	Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. *World Journal of Diabetes*, **2015**, 6, 943-60	4.7	38
120	Cardiac fibrosis in the ageing heart: Contributors and mechanisms. *Clinical and Experimental Pharmacology and Physiology*, **2017**, 44 Suppl 1, 55-63	3	37
119	Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. *PLoS ONE*, **2012**, 7, e49813	3.7	37
118	Differences in myocardial structure and coronary microvasculature between men and women with coronary artery disease. *Hypertension*, **2011**, 57, 186-92	8.5	37
117	Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. *International Journal of Cardiology*, **2013**, 167, 210-9	3.2	36
116	A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. *PLoS ONE*, **2012**, 7, e47160	3.7	35

115	SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease. *PLoS ONE*, **2014**, 9, e92227	3.7	34
114	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. *Journal of Hypertension*, **2011**, 29, 1175-84	1.9	34
113	Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. *European Journal of Pharmacology*, **2008**, 590, 290-6	5.3	34
112	Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. *Journal of Diabetes and Its Complications*, **2004**, 18, 309-15	3.2	34
111	Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. *Nephrology Dialysis Transplantation*, **2001**, 16, 1343-9	4.3	34
110	Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2011**, 26, 100-10	4.3	33
109	Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. *Connective Tissue Research*, **1999**, 40, 295-303	3.3	33
108	Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. *PLoS ONE*, **2015**, 10, e0119803	3.7	32
107	Dynamic synchrotron imaging of diabetic rat coronary microcirculation in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 370-7	9.4	32
106	Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. *Nephrology Dialysis Transplantation*, **2003**, 18, 1286-92	4.3	32
105	Obesity is associated with lower coronary microvascular density. *PLoS ONE*, **2013**, 8, e81798	3.7	31
104	Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. *Kidney International*, **2009**, 76, 23-31	9.9	31
103	In vivo visualization of albumin degradation in the proximal tubule. *Kidney International*, **2008**, 74, 1480-6	9.9	31
102	Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. *International Journal of Cardiology*, **2018**, 258, 192-198	3.2	30
101	FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. *European Journal of Heart Failure*, **2012**, 14, 549-62	12.3	30
100	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. *British Journal of Pharmacology*, **2011**, 162, 722-32	8.6	30
99	High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism. *Nephrology Dialysis Transplantation*, **2007**, 22, 3147-53	4.3	30
98	Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. *Cardiovascular Diabetology*, **2013**, 12, 111	8.7	28

97	Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome. *International Journal of Cardiology*, **2013**, 168, 1866-80	3.2	27
96	The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. *PLoS ONE*, **2013**, 8, e83687	3.7	27
95	Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: remodeling of the same sort. *Journal of Cardiovascular Electrophysiology*, **2011**, 22, 175-82	2.7	27
94	Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control. *Diabetologia*, **2008**, 51, 668-74	10.3	27
93	Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2007**, 293, F565-74	4.3	27
92	Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions. *Clinical and Experimental Pharmacology and Physiology*, **2015**, 42, 256-62	3	26
91	Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. *JACC Basic To Translational Science*, **2018**, 3, 213-226	8.7	26
90	Increased tissue kallikrein levels in type 2 diabetes. *Diabetologia*, **2010**, 53, 779-85	10.3	26
89	The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-□ in the regulation of macrophage inflammatory protein-3□ at early onset of diabetes. *International Journal of Biochemistry and Cell Biology*, **2011**, 43, 383-92	5.6	25
88	Neonatal calyceal dilation and renal fibrosis resulting from loss of Adamts-1 in mouse kidney is due to a developmental dysgenesis. *Nephrology Dialysis Transplantation*, **2005**, 20, 419-23	4.3	25
87	Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. *Journal of Pathology*, **2005**, 207, 483-92	9.4	25
86	Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. *Diabetes and Metabolism*, **2003**, 29, 386-92	5.4	24
85	Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. *Molecular and Cellular Endocrinology*, **1996**, 119, 175-84	4.4	24
84	Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. *Cellular Physiology and Biochemistry*, **2013**, 32, 1309-19	3.9	23
83	Atrial protective effects of n-3 polyunsaturated fatty acids: a long-term study in ovine chronic heart failure. *Heart Rhythm*, **2011**, 8, 575-82	6.7	23
82	The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. *Journal of Vascular Research*, **2001**, 38, 527-35	1.9	23
81	Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. *British Journal of Pharmacology*, **2020**, 177, 2906-2922	8.6	22
80	Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction. *Heart Lung and Circulation*, **2013**, 22, 122-32	1.8	22

79	Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. *Nephrology Dialysis Transplantation*, **2004**, 19, 262-3	4.3	22
78	Renin processing and secretion in adrenal and retina of transgenic (mREN-2)27 rats. *Kidney International*, **1994**, 46, 1583-7	9.9	22
77	Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. *Physiological Reports*, **2015**, 3, e12371	2.6	21
76	The role of dihydrosphingolipids in disease. *Cellular and Molecular Life Sciences*, **2019**, 76, 1107-1134	10.3	21
75	3Ƥ,4PDihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. *PLoS ONE*, **2011**, 6, e22777	3.7	20
74	Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. *Nephrology*, **2004**, 9, 7-13	2.2	20
73	Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. *International Journal of Cardiology*, **2013**, 167, 1027-37	3.2	19
72	Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. *Clinical and Experimental Pharmacology and Physiology*, **2011**, 38, 623-31	3	19
71	Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. *Nephrology Dialysis Transplantation*, **2009**, 24, 1782-90	4.3	18
70	Angiotensin II and the cardiac complications of diabetes mellitus. *Current Pharmaceutical Design*, **2007**, 13, 2721-9	3.3	18
69	Thioredoxin-interacting protein: a potential therapeutic target for treatment of progressive fibrosis in diabetic nephropathy. *Nephron*, **2015**, 129, 109-27	3.3	17
68	Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. *Kidney International*, **2006**, 69, 1954-60	9.9	17
67	Characterisation of a thymic renin-angiotensin system in the transgenic m(Ren-2)27 rat. *Molecular and Cellular Endocrinology*, **2002**, 194, 201-9	4.4	17
66	Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. *Journal of Molecular and Cellular Cardiology*, **2019**, 137, 119-131	5.8	16
65	Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. *Peptides*, **2010**, 31, 1523-30	3.8	16
64	Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. *Nephrology Dialysis Transplantation*, **2003**, 18, 2293-9	4.3	16
63	Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes. *Diabetes and Vascular Disease Research*, **2005**, 2, 76-80	3.3	16
62	Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 692-700	3	15

61	Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. *Diabetologia*, **2013**, 56, 675-9	10.3	15
60	Renal cellular hypoxia in adenine-induced chronic kidney disease. *Clinical and Experimental Pharmacology and Physiology*, **2016**, 43, 896-905	3	14
59	Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model. *Scientific Reports*, **2017**, 7, 18108	4.9	14
58	The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes. *Protein and Peptide Letters*, **2013**, 20, 1029-38	1.9	14
57	Characterization of cardiac remodeling in a large animal "one-kidney, one-clip" hypertensive model. *Blood Pressure*, **2010**, 19, 119-25	1.7	14
56	The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. *Nephrology*, **2007**, 12, 267-74	2.2	14
55	Angiotensin II influences ovarian follicle development in the transgenic (mRen-2)27 and Sprague-Dawley rat. *Journal of Endocrinology*, **2004**, 180, 311-24	4.7	14
54	Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 684-692	12.7	14
53	3Ḍ4PBis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6868-73	2.9	13
52	SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy. *Microvascular Research*, **2000**, 59, 61-71	3.7	13
51	Chronic intermittent hypoxia accelerates coronary microcirculatory dysfunction in insulin-resistant Goto-Kakizaki rats. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2016**, 311, R426-39	3.2	13
50	FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. *Clinical and Experimental Pharmacology and Physiology*, **2012**, 39, 650-6	3	12
49	Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. *Open Heart*, **2015**, 2, e000278	3	12
48	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. *Science Translational Medicine*, **2021**, 13, eabd5524	17.5	12
47	Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. *Cardiovascular Diabetology*, **2015**, 14, 92	8.7	11
46	Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. *BioMed Research International*, **2013**, 2013, 201475	3	11
45	FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. *PLoS ONE*, **2015**, 10, e0134392	3.7	11
44	Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. *Acta Diabetologica*, **2014**, 51, 771-82	3.9	10

43	Role of the EGF receptor in PPARΕmediated sodium and water transport in human proximal tubule cells. *Diabetologia*, **2013**, 56, 1174-82	10.3	10
42	A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. *International Journal of Cardiology*, **2013**, 168, 1174-85	3.2	10
41	Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction. *Cardiovascular Therapeutics*, **2013**, 31, 84-91	3.3	10
40	Myosin heads are displaced from actin filaments in the in situ beating rat heart in early diabetes. *Biophysical Journal*, **2013**, 104, 1065-72	2.9	10
39	Mitogen activated protein kinase signaling in the kidney: target for intervention?. *Signal Transduction*, **2006**, 6, 32-53		10
38	Novel approaches to the treatment of progressive renal disease. *Current Opinion in Pharmacology*, **2001**, 1, 183-9	5.1	10
37	Vasoactive renal factors and the progression of diabetic nephropathy. *Current Pharmaceutical Design*, **2004**, 10, 3373-84	3.3	10
36	Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome. *International Journal of Cardiology*, **2020**, 310, 128-136	3.2	9
35	Clinically relevant models of diabetic cardiac complications. *Circulation Research*, **2007**, 101, e78	15.7	9
34	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. *American Journal of Hypertension*, **2018**, 31, 1156-1163	2.3	8
33	Role of statins in diabetes complications. *Current Diabetes Reviews*, **2009**, 5, 165-70	2.7	8
32	Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats. *Nephrology*, **2008**, 13, 721-9	2.2	8
31	Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. *Nephron Experimental Nephrology*, **2008**, 109, e1-7		7
30	Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. *Heart Lung and Circulation*, **2019**, 28, 495-504	1.8	7
29	Chloride channel ClC-5 binds to aspartyl aminopeptidase to regulate renal albumin endocytosis. *American Journal of Physiology - Renal Physiology*, **2015**, 308, F784-92	4.3	6
28	Urotensin II and the kidney. *Current Opinion in Nephrology and Hypertension*, **2013**, 22, 107-12	3.5	6
27	Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. *International Journal of Cardiology*, **2010**, 143, 353-60	3.2	6
26	Renin inhibition: new potential for an old therapeutic target. *Hypertension*, **2005**, 46, 471-2	8.5	5

25	Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. *Physiological Reports*, **2020**, 8, e14448	2.6	5
24	Progressive diabetic nephropathy in the Ren-2 rat. *American Journal of Physiology - Renal Physiology* , **2007**, 292, F1662; author reply F1663	4.3	4
23	Experimental diabetic nephropathy: Is it relevant to the human disease. *Nephrology*, **2000**, 5, 177-185	2.2	4
22	Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings.. *Toxins*, **2022**, 14,	4.9	4
21	Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects. *Life Sciences*, **2021**, 272, 119267	6.8	4
20	High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 561-9	5.6	3
19	Prescription of physical activity in the management of high blood pressure in Australian general practices. *Journal of Human Hypertension*, **2019**, 33, 50-56	2.6	3
18	Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 628-645	5.6	2
17	BK virus RNA can be detected in archival renal transplant biopsies using the reverse trancription polymerase chain reaction. *Nephrology Dialysis Transplantation*, **2009**, 24, 661-6	4.3	2
16	Glucose transporters in animal models of diabetes and hypertension. *American Journal of Physiology - Renal Physiology*, **2006**, 291, F702-3; author reply F703-4	4.3	2
15	Drug therapy for the cardiac complications of diabetes. *Drug Discovery Today: Therapeutic Strategies*, **2004**, 1, 195-200		2
14	Nephropathy in type 2 diabetes: current therapeutic strategies. *Nephrology*, **2001**, 6, 266-269	2.2	2
13	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. *Future Cardiology*, **2017**, 13, 103-115	1.3	1
12	Protein kinase C inhibition ameliorates experimental mesangial proliferative glomerulonephritis. *Nephrology*, **2011**, 16, 649-55	2.2	1
11	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. *Vascular Pharmacology*, **2021**, 141, 106923	5.9	1
10	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment.. *Scientific Reports*, **2022**, 12, 859	4.9	0
9	NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction.. *Life Sciences*, **2021**, 289, 120220	6.8	0
8	Diabetic nephropathy without the diabetes: if not hyperglycaemia, then what?. *Nephrology*, **2007**, 12, 67-8	2.2	

7	Sandford Lloyd Skinner (1933–2005). *Hypertension*, **2005**, 46, 452-453	8.5
6	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. *Nephrology*, **2001**, 6, 290-297	2.2
5	THE IMPORTANCE OF BLOCKADE OF THE RENIN ANGIOTENSIN AND ENDOTHELIN SYSTEMS ON PROGRESSIVE RENAL INJURY IN SUBTOTALLY NEPHRECTOMISED RATS: USE OF COMBINATION REGIMENS. *Nephrology*, **2000**, 5, A109-A109	2.2
4	Rho Kinase Inhibition Improves Cardiac Cross-Bridge Dynamics in Early Diabetic Cardiomyopathy. *FASEB Journal*, **2015**, 29, 799.7	0.9
3	RE: ASK1, a new target in treating cardiorenal syndrome (CRS). *International Journal of Cardiology*, **2020**, 316, 207	3.2
2	RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis. *International Journal of Cardiology*, **2021**, 326, 156	3.2
1	RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome. *International Journal of Cardiology*, **2021**, 323, 260	3.2